Year 2004

• Pegasus Pharmaceuticals ("Pegasus") established Shanghai Tian-Bo Biosciences Inc. for drug development in China.

• PandiMex® injection has been granted market access in some parts of China, and sold as pharmaceuticals for hospital use. 

• In the province of British Columbia (BC), Canada, Pegasus established another subsidiary, PepMetric Technologies Inc. ("PepMetric").   PepMetric specializes in the design, modification and synthesis of novel peptide molecules with high purity, design and synthesis of large flux of peptide array chips, detection of interactions among peptides and polypeptides, the antibody epitopes, and discovery of bindings of target proteins with peptides, and a large sample database of epitopes and peptide molecules.

• Pegasus established a global network of the Careseng® Cancer Institute Inc.  More than a dozen clinics have joined the network.

• Pegasus set up Hongsheng Bio-Tech Co., Ltd. in Taiwan.

• Pegasus' headquarter is moved 110-11800 River Road, Richmond, BC, Canada, V6X 1Z7.

• Pegasus' Chief Scientist was invited to the third International Conference & Exposition on Traditional Medicine in Beijing, China, and gave a keynote speech on "Dammarane Sapogenins with Multiple Anti-cancer Mechanisms".

• From in-vitro and in-vivo experiments such as animal testing and clinical studies, dammarane Sapogenins (aglycone ginsenosides), the active ingredients of Careseng® series, have shown to inhibit tumor growth and induce apoptosis of cancer cells.

• Panagin Pharmaceuticals Inc. applied a Chinese patent on "A Novel Anti-cancer Compound, its IV Injection and Applications" (200410075340.7).

• Pegasus applied for a Chinese patent on "Method of Increasing in-stomach Bioavailabilities of Saponins, Sapogenins and Their Compositions and Uses Thereof" (200410084849.8).

• A research paper on "Aglycone Protopanaxadiol, a Ginseng Saponin Inhibits P-glycoprotein and Sensitizes Chemotherapy Drugs on Multidrug Resistant Cancer Cells", was published in the annual meeting of the American Society of Clinical Oncology (ASCO).

• A research paper on "An Aglycone Ginsenoside Induces Apoptosis and Blocks P-glycoprotein in Multidrug Resistance Cancer Cells" was published in the annual meeting of the American Association for Cancer Research (AACR).